Staar Surgical (STAA) provided the following statement in response to a report issued by Glass, Lewis & Co. related to Staar’s pending merger with Alcon (ALC): “The Staar Board of Directors and management team strongly disagree with the recommendation issued by Glass Lewis. Alcon is paying Staar stockholders a 59% premium to the 90-day VWAP, whereas Broadwood’s proposal to vote down the merger could allow Broadwood to take control without paying any premium to other stockholders.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Broadwood: Glass Lewis uring Staar Surgical investors to vote against Alcon deal
- Defender Capital says opposes Staar Surgical’s proposed sale to Alcon
- Yunqi Capital urges STAAR shareholders to oppose Alcon merger
- Staar Surgical issues statement in response to claims made by Broadwood Partners
- Broadwood Partners urges Staar Surgical holders to vote against Alcon merger